AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy

Recruitingn/aAges 18 Years - anyAllMemorial Sloan Kettering Cancer Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Cohorts A and B * Patients must be 18 years of age or older * Patients must have adequate end organ function for CAR T cell therapy * Eastern Cooperative Group (ECOG) performance status of 0 to 2 * Meet cardiac, pulmonary, hematologic, hepatic, and renal requirements for CART therapy as described in corresponding product package insert * No evidence of central nervous system disease at study entry * Fluent and able to communicate well enough in English to complete the study assessments and provide informed consent, in the judgment of the consenting professional. o Patients who report that English is not their primary language will be asked the US Census English proficiency question: "How well do you speak English," and the answer "very well" will be required * Additional Cohort Specific Inclusion Criteria: Cohort A Subjects must meet all of the following criteria to be enrolled in the Lymphoma cohort of this study * Planned treatment with commercial CD19-specific CAR T cells (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexacabtagene autoleucel) for lymphoma. * Additional Cohort Specific Inclusion Criteria: Cohort B Subjects must meet all of the following criteria to be enrolled in the Multiple Myeloma cohort of this study * Planned treatment with commercial BCMA CAR T cell therapy ciltacabtagene autoleucel for multiple myeloma Exclusion Criteria: All Cohorts * Signs and/or symptoms of central nervous system cancer (e.g., metastases, leptomeningeal disease) as determined by their physician, medical records, or by a brain MRI, either at the time of enrollment or during the study period. * Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report * History of neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report * A history of epilepsy as per medical records or patient report * Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report * Evidence of visual or auditory impairment that would preclude completion of the assessments, as per medical records or patient report * Contraindications to MRI examinations as per standard screening guidelines used in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers or defibrillators, stents, claustrophobia)
๐Ÿ’Š

What it tests

  • neurocognitive evaluations
  • brain MRIs
  • Blood samples
๐Ÿ“

Where

1 site
Memorial Sloan Kettering Cancer Center
New York, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy